Trial reportClinical pharmacology and therapeutics2018
Potent Anti-Inflammatory and Pro-Resolving Effects of Anabasum in a Human Model of Self-Resolving Acute Inflammation.
Open access · hybridAbstract readComparative StudyRandomized Controlled Trial
In one paragraph
Trial report in Clinical pharmacology and therapeutics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed
5.2field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 75 citations in OpenAlex.
- Long-Term Safety and Efficacy of Lenabasum, a Cannabinoid Receptor Type 2 Agonist, in Patients with Dermatomyositis with Refractory Skin Disease: Follow-Up Data from a 3-Year Open-Label Extension Study.JID innovations : skin science from molecules to population health · 2025Trial
- Safety and Efficacy of Lenabasum, a Cannabinoid Receptor Type 2 Agonist, in Patients with Dermatomyositis with Refractory Skin Disease: A Randomized Clinical Trial.The Journal of investigative dermatology · 2022Trial
- Safety and Efficacy of Lenabasum in a Phase II, Randomized, Placebo-Controlled Trial in Adults With Systemic Sclerosis.Arthritis & rheumatology (Hoboken, N.J.) · 2020Trial
- Cannabinoids for Dermatological Applications: Mechanistic Insights, Clinical Evidence, and Emerging Nanotechnology-Enabled Delivery Strategies.Pharmaceutics · 2026Review
- Interactions Between Plant-Derived Psychoactive Substances andMolecules (Basel, Switzerland) · 2026Review
- Epoxy-oxylipins direct monocyte fate in inflammatory resolution in humans.Nature communications · 2026Article
- Article
- Specialized Pro-Resolving Lipid Mediators in Pulmonary Diseases: Molecular and Therapeutic Implications.Molecules (Basel, Switzerland) · 2025Review
- A new model measuring bacterial phagocytosis and phagolysosomal oxidation in humans using the intradermal injection of methylene blue-labeled Escherichia coli.Journal of leukocyte biology · 2025Article
- Review of methodology and re-analysis of lipidomic data focusing on specialised pro-resolution lipid mediators (SPMs) in a human model of resolving inflammation.International journal of experimental pathology · 2025Review
- Is Lipid Metabolism of Value in Cancer Research and Treatment? Part II: Role of Specialized Pro-Resolving Mediators in Inflammation, Infections, and Cancer.Metabolites · 2024Review
- The impact of trauma relevant concentrations of prostaglandin EFrontiers in immunology · 2024Article
- Cannabidiol acts as molecular switch in innate immune cells to promote the biosynthesis of inflammation-resolving lipid mediators.Cell chemical biology · 2023Article
- Resolvins and cysteinyl-containing pro-resolving mediators activate resolution of infectious inflammation and tissue regeneration.Prostaglandins & other lipid mediators · 2023Review
- Allosteric Activation of 15-Lipoxygenase-1 by Boswellic Acid Induces the Lipid Mediator Class Switch to Promote Resolution of Inflammation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Article
- Mesenchymal stromal cells and alpha-1 antitrypsin have a strong synergy in modulating inflammation and its resolution.Theranostics · 2023Article
- Cannabinoid Compounds as a Pharmacotherapeutic Option for the Treatment of Non-Cancer Skin Diseases.Cells · 2022Review
- Neuroinflammation and neuroprogression in depression: Effects of alternative drug treatments.Brain, behavior, & immunity - health · 2022Review
- Analysis of Anti-Cancer and Anti-Inflammatory Properties of 25 High-THC Cannabis Extracts.Molecules (Basel, Switzerland) · 2022Article
- Cannabinoids for the Treatment of Dermatologic Conditions.JID innovations : skin science from molecules to population health · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 4 institutions in 2 countries.
Madhur P MotwaniCentre for Clinical Pharmacology and Therapeutics, Division of Medicine, University College London, London, UK.
Frances BennettCentre for Clinical Pharmacology and Therapeutics, Division of Medicine, University College London, London, UK.
Paul C NorrisCenter for Experimental Therapeutics and Reperfusion Injury, Department of Anesthesiology, Perioperative, and Pain Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Alexander A MainiCentre for Clinical Pharmacology and Therapeutics, Division of Medicine, University College London, London, UK.
Marc J GeorgeCentre for Clinical Pharmacology and Therapeutics, Division of Medicine, University College London, London, UK.
Justine NewsonCentre for Clinical Pharmacology and Therapeutics, Division of Medicine, University College London, London, UK.
Alice HendersonCentre for Clinical Pharmacology and Therapeutics, Division of Medicine, University College London, London, UK.
Adrian J HobbsWilliam Harvey Research Institute, Heart Centre, Barts & the London School of Medicine, Queen Mary University of London, London, UK.
Mark TepperCorbus Pharmaceuticals, Norwood, Massachusetts, USA.
Barbara WhiteCorbus Pharmaceuticals, Norwood, Massachusetts, USA.
Charles N SerhanCenter for Experimental Therapeutics and Reperfusion Injury, Department of Anesthesiology, Perioperative, and Pain Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Raymond MacAllisterCentre for Clinical Pharmacology and Therapeutics, Division of Medicine, University College London, London, UK.
Derek W GilroyCentre for Clinical Pharmacology and Therapeutics, Division of Medicine, University College London, London, UK.
University College London · GBCorbus Pharmaceuticals (United States) · USHarvard University · USQueen Mary University of London · GB
Funding
Resolution Mechanisms in Acute Inflammation: Resolution PharmacologyP01GM095467 · NIGMS · BRIGHAM AND WOMEN'S HOSPITAL · PI PETASIS, NICOS A · 2011 to 2020
$14.8MNIGMS NIH HHS P01 GM095467
Abstract
Anabasum is a synthetic analog of Δ
Indexed as
AdolescentAdultAnti-Inflammatory AgentsCannabinolCytokinesDermatitisDose-Response Relationship, DrugDronabinolEscherichia coliEscherichia coli InfectionsHost-Pathogen InteractionsHumansInflammation MediatorsLipid MetabolismMaleMiddle AgedanabasumAnti-Inflammatory AgentsCannabinolCytokinesDronabinolInflammation MediatorsPrednisolone
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.